Introgen obtains key patent obtained for p53-targeted chemotherapy.
D000077584:2-Methoxyestradiol; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology*; D016158:Genes, p53 / Q000187:drug effects*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010330:Patents as Topic; D014481:United States
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D004958:Estradiol; D000077584:2-Methoxyestradiol